Japan Pharmaceutical Sector
Torreya Partners has been active as an advisor in the Japanese pharmaceutical sector since our inception.
Senior personnel at Torreya have been involved in over $1 billion of pharma licensing and M&A transactions involving Japanese life sciences companies.
Recent projects have included representing Teikoku Pharma in their acquisition of a U.S. company in transdermals, Travanti Pharma; representing ProEthic Pharma in their sale to Kowa and representing Shionogi in the divestiture of a variety of commercial assets in three separate transactions.
Torreya takes pride in servicing both large Japanese pharmaceutical companies and many smaller players that, nonetheless, have substantial ambitions.
We are currently active on a variety of projects involving Japanese clients which principally involve in licensing, out licensing, cross-border M&A deals or consulting. Our practice in Japan is led by Chuck Dimmler who has been visiting Japan in various capacities since the 1960s.
Selected Past Deals
Sale of Naprelan to Alvogen
Divestiture of Three Pediatric Drugs to Concordia Pharmaceuticals
Divestiture of Cuvposa to Merz
Acquisition of Travanti Pharma
Sale to Kowa Pharmaceuticals